Glimipride Me ormin(SR) Voglibose Tablet - Manufacturers & Suppliers - Third Party Contract Manufacturing - PCD Pharma Franchise
Coravog GM1 tablets contain Glimipride+ Voglibose + Metformin
It belongs to the category of alpha-glucosidase inhibitor which mainly useful in management of post- prandial blood glucose in diabetic patients. It helps in delaying the absorption of glucose.
It is also an oral antidiabetic drug which belongs to biguanide class which is the first line treatment for type 2 diabetes mellitus. It causes suppression of glucose production by liver.
Glimepiride is a sulfonylurea anti-diabetic drug. It belongs to third generation anti-diabetic drug. It is also an oral antidiabetic drug which belongs to biguanide class which is the first line treatment for type 2 diabetes mellitus. It causes suppression of glucose production by liver.
• Treatment ofhyperglycemia
• Mainly post prandial blood glucose
• Macrovascular complications
Dosage: As directed by physician
Mechanism of action
Voglibose is an alpha amylase glucosidase inhibitor which produces its action by inhibiting the alpha glucosidase present in the intestinal wall which causes reduced absorption of disaccharides, dextrin and starch in the intestine. This helps in reduction of rise in post prandial glucose. All the actions produces by the drug are not involving stimulation of insulin so it reduces the risk of hypoglycemia in patients.
Metformin : It decreases gluconeogenesis in liver and also decreases the intestinal absorption of glucose. It also improves the sensitivity of insulin.
Glimepiride stimulates the secretion of insulin granules from the pancreatic beta cells and improves the sensitivity of peripheral tissues to insulin to increase peripheral glucose uptake, thus reducing plasma blood glucose levels and glycated hemoglobin (HbA1C) levels.
After oral administration of the drug is poorly absorbed. The drug slowly attains peak plasma concentration
The majority of the drug is present in the gastro intestinal tract where with the presence of glucosidase inhibitors attains its pharmacological actions. The drug is metabolized mainly by intestinal enzymes.
The maximum amount of drug is excreted in urine and feces.
• Hypersensitivity to any of the ingredient present in the drug
• Diabetic ketoacidosis
• Renal dysfunction and failure
• Severe infection
• Inflammatory bowel disease
• Renal dysfunction
• Hypoglycemic episodes
• Hepatic dysfunction